Individualised vancomycin doses for paediatric burn patients to achieve PK/PD targets

Burns

Volumn 39, Issue 3, 2013, Pages 445-450

  Gomez, David S ^a   Campos, Edvaldo V ^a   De Azevedo, Rodrigo P ^a   Silva Jr , João Manoel Da ^a   Ferreira, Marcus C ^a   Sanches Giraud, Cristina ^a   Silva Jr , Carlindo Vieira ^a   Santos, Silvia R C J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dose adjustment; Pediatric burn patients; PK PD correlation; Trough; Vancomycin

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; BURN; BURN PATIENT; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LIMIT OF DETECTION; LUNG BURN; MALE; MINIMUM INHIBITORY CONCENTRATION; OPEN STUDY; PEDIATRICS; PLASMA CLEARANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BURNS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84875222734     PISSN: 03054179     EISSN: 18791409     Source Type: Journal    
DOI: 10.1016/j.burns.2012.07.005     Document Type: Article

References (28)

1. J.L. Reed, and W.J. Pomerantz Emergency management of pediatric burns Pediatr Emerg Care 21 2 2005 118 129
2. L.K. Branski, A. Al-Mousawi, H. Rivero, M.G. Jeschke, A.P. Sanford, and D.N. Herndon Emerging infections in burns Surgical Infections 10 5 2009 389 397
3. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2 2008 193 200
4. A.G.A.C. Reis, and S.J.F.E. Grisi Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections J Pediatr 72 4 1996 225 229
5. R.E. Wrishko, M. Levine, D. Khoo, P. Abbott, and D. Hamilton Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients Ther Drug Monit 22 5 2000 522 531
6. C. Giuliano, K. Haase, and R. Hall Use of vancomycin pharmacokinetic- pharmacodynamic properties in the treatment of MRSA infections Expert Rev Anti Infec Ther 8 1 2010 95 106
7. A. Frymoyer, A.L. Hersh, L.Z. Benet, and B.J. Guglielmo Current recommended dosing of vancomycin for children with invasive methicillin- resistant Staphylococcus aureus infections is inadequate J Pediatr Infect Dis 28 5 2009 398 402
8. M.J. Rybak, B.M. Lomaestro, J.C. Rotschafer, R.C. Moellering Jr. , W.A. Craig, and M. Billeter Therapeutic monitoring of vancomycin in adults Pharmacotherapy 29 11 2009 1275 1279
9. J.C. Garrelts, and J.D. Peterie Altered vancomycin dose vs serum concentration relationship in burn patients Clin Pharmac Therap 44 1 1988 9 13
10. M. Rybak, L. Albrecht, J. Berman, L. Warbasse, and C. Svensson Vancomycin pharmacokinetics in burn patients and intravenous drug abusers Antimicrob Agents Chemother 34 1990 792 795
11. M. Elligsen, S.A.N. Walker, S.E. Walter, and A. Simor Optimizing initial vancomycin dosing in burn patients Burns 37 2011 406 414
12. D.G. Greenhalgh, J.R. Saffle, and J.H. Holmes American Burn Association consensus conference to define sepsis and infection in burns J Burn Care Res 28 2007 776 790
13. G.J. Schwartz, G.B. Haycack, C.M. Edelmann, and A. Spitzer A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine Pediatrics 58 1976 259 263
14. K.J.V. Lopez, D.F. Bertoluci, K.M. Vicente, A.M. Dell'aquilla, and S.R.C.J. Santos Simultaneous determination of cefepime, vancomycin and imipenem in human plasma of burn patients by high-performance liquid chromatography J Chromatog B 860 2007 241 245
15. EUCAST-European Committee of antimicrobial susceptibility testing. MIC distribution. Available at: http://www.eucast.org/mic-distributions; Accessed in 15/02/2011.
16. N. Revilla, A. Marín-Suárez, M.P. Pérez, F.M. González, and M.M.F. Gatta Vancomycin dosing assessment on intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation Br J Clin Pharmacol 70 2 2010 201 212
17. J.S. Kang, and M.H. Lee Overview of therapeutic drug monitoring Korean J Int Med 24 1 2009 1 10
18. J.K.K. Machado, R. Feferbaum, C.E. Kobayashi, C. Sanches, and S.R.C.J. Santos Vancomycin pharmacokinetics in preterm infants Clinics 62 4 2007 405 410
19. M.L. Glover, E. Cole, and J. Wolfsdorf Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function J Crit Care 15 1 2000 1 4
20. L.S. Eiland, T.M. English, and E.H. Eiland Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients Ann Pharmacother 45 5 2011 582 589
21. P. Lamarre, D. Lebel, and M.P. Ducharme A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a native population Antimicrob Agents Chemother 44 2 2000 278 282
22. A. Onishi, Y. Yano, T. Ishibashi, T. Katsube, and T. Oguma Evaluation of bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients Drug Metab Pharmacokinet 20 6 2005 415 422
23. M. Yasuhara, T. Iga, H. Zenda, K. Okumura, T. Oguma, and Y. Yano Population pharmacokinetics of vancomycin in Japanese pediatric patients Ther Drug Monitoring 20 6 1998 612 618
24. B. Blanchet, V. Jullient, C. Vinsonneau, and M. Tod Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients Clin Pharmacokinet 47 10 2008 635 654
25. M.J. Weinbren Pharmacokinetics of antibiotics in burn patients J Antimicrob Chemother 44 1999 319 327
26. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patients Crit Care Med 37 3 2009 840 851
27. R.H. Yang, X.Z. Rong, R. Hua, and T. Zhang Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn Burns 35 1 2009 75 79
28. J.A. Bosso, J. Nappi, C. Rudisill, M. Wellein, P.B. Bookstaver, and J. Swindler Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial Antimicrob Agents Chemother 55 12 2011 5475 5479